Glass Lewis and Institutional Shareholder Services recommend MYM shareholders to vote FOR the transaction with IMCC
Over 90% of the committed and recognized ordinary shares are voted in favor of the transaction
VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) – MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) (“MYM” or the “Company”) is pleased to announce that Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”), the two leading independent voting consultancies that provide voting recommendations to shareholders, each issued positive opinions on the proposed acquisition of MYM by IM Cannabis Corp. (“IMCC”) announced on April 1, 2021 (the “Transaction”). Glass Lewis and ISS recommend that MYM shareholders vote in favor of the resolution to be voted on at the extraordinary shareholders’ meeting to be held on July 5, 2021.
A total of 66 and 2/3 of all common shares voted are required to approve the transaction as well as a majority of minority votes in accordance with Multilateral Instrument 61-101. Protection of holders of minority securities in special transactions (“IM 61-101”). To date, including those who have entered into support agreements, over 90% of all common shares pledged and accounted for are voted in favor of the transaction.
The votes attached to the common shares held by Michael Wiener, Chief Executive Officer (14,214,286 common shares held), Laird Choi, Vice-President, Human Resources and Corporate Services (4,652,837 common shares held) and Robert Wolf, independent director (2,857,143 common shares held) will be excluded for the purposes of the approval of the Transaction required by NI 61-101.
MYM shareholders of record at the close of business on May 31, 2021 are entitled to vote at the Special Meeting. Full details of the transaction and the matters to be voted on at the Meeting are described in the Management Information Circular and Meeting Materials which were mailed to shareholders on or before June 10, 2021. All documents relating to the Meeting are available for download from SEDAR at www.sedar.com.
To proactively address the unprecedented public health impact of COVID-19, the meeting will be held in a virtual-only format that will take place via a live audio webcast online at https: // web .lumiagm.com / 419800178 at 11:00 a.m. (Vancouver time) July 5, 2021.
About MYM Nutraceutiques Inc.
MYM is a Canadian grower, processor and distributor of premium quality cannabis through its two wholly owned subsidiaries – SublimeCulture Inc., in Laval, QC and Highland Grow Inc., in Antigonish, NS.
MYM shares trade in Canada, Germany and the United States under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY ).
IN THE NAME OF THE MYM BOARD
Michael Wiener, CEO
MYM Nutraceuticals Inc.
Toll free: (800) 232-0316
Email: [email protected]
Stay up to date with MYM on our social media channels:
About IM Cannabis Corp.
IMC is an MCO in the medical and adult recreational cannabis industry, headquartered in Israel and with operations in Israel, Germany and Canada. Over the past decade, the company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its activities to provide intellectual property related services to the medical cannabis industry.
In Europe, IMC operates through Adjupharm GmbH (“Adjupharm“), a German-based subsidiary and an EU-certified medical cannabis processor and distributor. IMC’s European presence is reinforced by strategic alliances with various EU-GMP pan-European growers and distributors to take advantage of the growing demand of medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.
In Canada, IMC operates through Trichome JWC Acquisition Corp. (“JWCJWC is a licensed producer located in Kitchener, Ontario, which sells cannabis flowers, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and Wagners brands. JWC maintains standards. bred to provide clean, uniform and aeroponic products – premium quality cannabis products for medical patients and the adult market across Canada and the world. On March 31, 2021, IMC entered into a definitive agreement to acquire MYM Nutraceuticals Inc . (“MYM“) and its licensed production subsidiary, Highland Grow Inc. This transaction, if completed, will strengthen IMC’s goal of being one of the world’s leading producers and suppliers of premium cannabis.
Forward-looking information disclaimer
This press release contains “forward-looking information” within the meaning of applicable securities laws regarding MYM’s current expectations, estimates and projections regarding the future, based on certain assumptions made in light of experience and knowledge. perceptions of historical trends. Although MYM believes that the expectations represented by such forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Investors should not place undue reliance on forward-looking information, which is inherently uncertain. Actual results may differ materially from the expectations represented in the forward-looking information contained in this press release.
Forward-looking information is often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “probable” and ” intend ”and statements that an event or result“ could ”,“ will ”,“ should ”,“ could ”or“ could ”occur or be achieved and other similar expressions. The forward-looking information contained in this press release includes (i) statements regarding the expected vote of persons who have contracted to vote in favor of the Transaction but have not yet submitted their proxy, and (ii) statements regarding the shareholding of certain persons who will be excluded from the vote for the purpose of approving the Transaction required by NI 61-101.